Bedford, MA-based Hologic (NASDAQ: [[ticker:HOLX]]) announced that the FDA has approved its permanent contraception device, called Adiana. Offering a less-invasive alternative to tubal ligation—a surgical procedure that is one of the most common forms of contraception worldwide—the device can be inserted via catheter through the vagina in a 15-minute procedure. Hologic gained European approval for the device this past January.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
